Research Idea
Research content for general circulation. Not individualized advice.Ā Methodology & Disclosures
Near-term earnings momentum trade: stock rallied about 32% over 21 trading days and made a fresh window high, with Q2 2026 results due on 2026-07-23 as a potential catalyst.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ā¢ Quarterly Turnaround ā¢ Strong Liquidity ā¢ High Valuation ATRC's improving quarterly profitability, strong cash generation, and low leverage are offset by uneven annual returns and a demanding valuation.
Price Behavior
Key Price Behavior Insights: ā¢ Higher highs ā¢ Resistance test ā¢ Pullback risk Support Level: $56.22ā$57.14 (deeper: $52.96ā$53.73) Resistance Level: $59.12 ATRC gained ~22% over the last month and remains bullish above $56.22ā$57.14, but investors should watch for confirmation above $59.12 amid elevated pullback risk.
Sentiment & News
Key News Insights: ā¢ 52-Week High ā¢ Product Platform ā¢ Competitive Pressure AtriCure's stock momentum and product breadth support a constructive outlook, though competitive ablation pressures and modest insider selling warrant monitoring.
AI Summary
ATRC's investment case has shifted to a profitability-inflection story, with 77% gross margins, positive earnings, and strong free cash flow supporting durable operating leverageābut at ~180x earnings and 46.8x EV/EBITDA, investors should await repeated margin execution and clinical-adoption progress before chasing a stock already above consensus targets.
Description
AtriCure develops, manufactures and sells surgical systems and devices used to ablate cardiac tissue and intercostal nerves, serving hospitals and cardiac centers in the United States and internationally. Its portfolio includes radiofrequency and cryoablation systems, epicardial appendage occlusion and suture-based closure solutions, and a range of supporting instruments and disposables for electrophysiology and cardiac surgery. The company distributes products through a mix of independent distributors and direct sales teams and is headquartered in Mason, Ohio; it was incorporated in 2000.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Jul 16 | Jul 23 | ATRC | AtriCure, Inc. | Near-term earnings momentum trade: stock rallied about 32% over 21 trading days and made a fresh window high, with Q2 2026 results due on 2026-07-23 as a potential catalyst. | Closed | -7.4% |
| Jan 12 | Jan 19 | ATRC | AtriCure, Inc. | AtriCure exhibits strong short-term growth supported by 16% revenue increase in Q3, positive EBITDA growth, cash flow improvement, clinical pipeline advancements, and strong technical breakout despite near-term technical softness. | Closed | +3.8% |